Oric® Pharmaceuticals 已正式启动一项名为Himalayas-1的III期临床试验。该试验旨在评估其候选药物Rinzimetostat与拜耳公司的Nubeqa® (darolutamide)联合用药方案,用于治疗转移性去势抵抗性前列腺癌(MCRPC)。此项研究的推进得到了与拜耳公司的临床合作支持。
Oric® Pharmaceuticals 已正式启动一项名为Himalayas-1的III期临床试验。该试验旨在评估其候选药物Rinzimetostat与拜耳公司的Nubeqa® (darolutamide)联合用药方案,用于治疗转移性去势抵抗性前列腺癌(MCRPC)。此项研究的推进得到了与拜耳公司的临床合作支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.